Teva Pharmaceutical Industries Ltd. June 1 said that it has commercially launched its generic copy of Bayer Schering Pharma AG’s Yaz contraceptive tablets (drospirenone and ethinyl estradiol), which Teva is calling Gianvi.
At the same time Teva launched Gianvi, however, Berlin-based Bayer sued Teva over the launch in federal court in Delaware, claiming that the Gianvi launch infringes three Bayer patents on the drug (Bayer Schering Pharma AG v. Teva Pharmaceutical Industries Ltd.).
Specifically, Bayer’s suit asks the court to halt Food and Drug Administration approval of Gianvi until after the patents and any associated exclusivities expire on ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.